Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals

Vaccine

Volumn 29, Issue 16, 2011, Pages 3021-3030

  Bernatchez, Chantale ^a   Zhu, Kuichin ^a   Li, Yufeng ^a   Andersson, Helen ^a   Ionnides, Constantin ^a   Fernandez Vina, Marcelo ^a   Cano, Pedro ^a   Cooper, Laurence ^a   Abbruzzese, James ^a   Hwu, Patrick ^a   Chang, David Z ^a   Radvanyi, Laszlo G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Epitope; HLA A0201; Survivin; T cell; Tumor antigen

Indexed keywords

EPITOPE; GLUTAMYLLEUCYLMETHIONYLLEUCYLGLYCYLGLUTAMYLPHENYLALANYLLEUCYLLYSYLLEUCINE; GLUTAMYLLEUCYLTHREONYLLEUCYLGLYCYLGLUTAMYLPHENYLALANYLLEUCYLLYSYLLEUCINE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA C ANTIGEN; SURVIVIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CROSS REACTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; T LYMPHOCYTE; TUMOR CELL; VACCINATION; WILD TYPE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES;

EID: 79953212867     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.115     Document Type: Article

References (30)

1. Oble D.A., Loewe R., Yu P., Mihm M.C. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009, 9:3.
2. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.-B., Becker J.C., thor Straten P. Spontaneous cytotoxic T-cell responses against Survivin-derived MHCClass I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001, 61(16 (August 1)):5964-5968.
3. Reker S., Becker J.C., Svane I.M., Ralfkiaer E., Straten P.T., Andersen M.H. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 2004, 108(6):937-941.
4. Reker S., Meier A., Holten-Andersen L., Svane I.M., Becker J.C., thor Straten P., et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004, 3(2 (February)):173-179.
5. Andersen M.H., Pedersen L.O., Becker J.C., Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein Survivin in cancer patients. Cancer Res 2000, 61(3 (February 1)):869-872.
6. Hirohashi Y., Torigoe T., Maeda A., Nabeta Y., Kamiguchi K., Sato T., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002, 8(6 (June)):1731-1739.
7. Otto K., Andersen M.H., Eggert A., Keikavoussi P., Pedersen L.O., Rath J.C., et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005, 23(7 (January 4)):884-889.
8. Tsuruma T., Hata F., Torigoe T., Furuhata T., Idenoue S., Kurotaki T., et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004, 2(1 (June 13)):19.
9. Honma I., Kitamura H., Torigoe T., Takahashi A., Tanaka T., Sato E., et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009.
10. Tsuruma T., Iwayama Y., Ohmura T., Katsuramaki T., Hata F., Furuhata T., et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008, 6:24.
11. Wobser M., Keikavoussi P., Kunzmann V., Weininger M., Andersen M.H., Becker J.C. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006, 55(10 (October)):1294-1298.
12. Fuessel S., Meye A., Schmitz M., Zastrow S., Linne C., Richter K., et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006, 66(8 (June 1)):811-821.
13. Zhu K., Lizee G., Cano P., Fernando-Vina M., Ji B., Abbruzzese J.L., et al. HLA-A0201 positive pancreatic cell lines: new findings and discrepancies. Cancer Immunol Immunother 2007, 56(5 (May)):719-724.
14. Radvanyi L.G., Banerjee A., Weir M., Messner H. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 1999, 50(5 (November)):499-509.
15. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997, 100(11 (December 1)):2757-2765.
16. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174(10 (May 15)):6332-6339.
17. Stuber G., Leder G.H., Storkus W.T., Lotze M.T., Modrow S., Szekely L., et al. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol 1994, 24(3 (March)):765-768.
18. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996, 157(6 (September 15)):2539-2548.
19. Casati C., Dalerba P., Rivoltini L., Gallino G., Deho P., Rini F., et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003, 63(15 (August 1)):4507-4515.
20. Andersen M.H., Becker J.C., Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005, 4(5 (May)):399-409.
21. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993, 74(5 (September 10)):929-937.
22. Kotturi M.F., Scott I., Wolfe T., Peters B., Sidney J., Cheroutre H., et al. Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol 2008, 181(3 (August 1)):2124-2133.
23. Obar J.J., Khanna K.M., Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008, 28(6 (June)):859-869.
24. De Silva-Udawatta M., Kumar S.R., Greidinger E.L., Hoffman R.W. Cloned human TCR from patients with autoimmune disease can respond to two structurally distinct autoantigens. J Immunol 2004, 172(6 (March 15)):3940-3947.
25. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998, 19(9 (September)):395-404.
26. Lichterfeld M., Williams K.L., Mui S.K., Shah S.S., Mothe B.R., Sette A., et al. T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily. Int Immunol 2006, 18(7 (July)):1179-1188.
27. Höllsberg P. Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein–Barr Virus. Scand J Immunol 2002, 55(2):189-195.
28. Lacey S.F., Villacres M.C., La Rosa C., Wang Z., Longmate J., Martinez J., et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Human Immunol 2003, 64(4):440-452.
29. Runge L.A., Davey F.R., Goldberg J., Boyd P.R. The inheritance of Felty's syndrome in a family with several affected members. J Rheumatol 1986, 13(1 (February)):39-42.
30. Helgadottir H., Andersson E., Villabona L., Kanter L., van der Zanden H., Haasnoot G.W., et al. The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 2009.